| pubmed-article:9546433 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9546433 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
| pubmed-article:9546433 | lifeskim:mentions | umls-concept:C0018282 | lld:lifeskim |
| pubmed-article:9546433 | lifeskim:mentions | umls-concept:C0033640 | lld:lifeskim |
| pubmed-article:9546433 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:9546433 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:9546433 | lifeskim:mentions | umls-concept:C2350701 | lld:lifeskim |
| pubmed-article:9546433 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:9546433 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:9546433 | lifeskim:mentions | umls-concept:C2003941 | lld:lifeskim |
| pubmed-article:9546433 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:9546433 | pubmed:dateCreated | 1998-4-29 | lld:pubmed |
| pubmed-article:9546433 | pubmed:abstractText | The clonogenic cells of chronic myeloid leukaemia (CML), unlike normal haemopoietic progenitor cells, are resistant to the growth inhibitory effects of the chemokine macrophage inflammatory protein-1 alpha (MIP-1alpha). CML is also relatively resistant to chemotherapy and the disease is difficult to cure using conventional therapeutic routes. CML is associated with increased abl oncogene protein tyrosine kinase (PTK) activity. Here, we have tested the hypothesis that these aberrant responses to MIP-1alpha and the relative resistance to chemotherapy are directly related to this increased abl PTK activity in primitive haemopoietic cells. To do this we have expressed a temperature sensitive abl PTK in a growth factor dependent, multipotent stem cell line (FDCP-Mix) in which growth is normally suppressed by MIP-1alpha. In FDCP-Mix cells expressing the ts v-abl PTK and grown at the restrictive temperature for PTK activity the cells were relatively sensitive to cytotoxic agents such as cytosine arabinoside and 5-fluorouracil but MIP-1alpha could induce growth inhibition and confer some degree of protection from these agents. At the permissive temperature for abl PTK, the cells were relatively resistant to cytotoxic drugs and MIP-1alpha treatment neither induced growth inhibition nor protected the cells from cytotoxic drug induced cell death. This lack of response to MIP-1alpha was not due to receptor down modulation as neither the affinity nor the number of 125I-MIP-1alpha binding sites was altered by activating Abl PTK. However, MIP-1alpha mediated increases in cytosolic Ca2+ levels were abrogated by switching cells to the permissive temperature for Abl PTK activity. These data suggest that the relative resistance of CML progenitor cells to therapeutic drugs and the lack of response to MIP-1alpha occurs as a direct consequence of abl PTK activity and involves desensitisation of signal transduction events stimulated by MIP-1alpha receptors. Thus one contributory mechanism to transformation of primitive haemopoietic cells is abrogation of response to a growth inhibitor. | lld:pubmed |
| pubmed-article:9546433 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9546433 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9546433 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9546433 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9546433 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9546433 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9546433 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9546433 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9546433 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9546433 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9546433 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9546433 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9546433 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9546433 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9546433 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:9546433 | pubmed:issn | 0950-9232 | lld:pubmed |
| pubmed-article:9546433 | pubmed:author | pubmed-author:DexterT MTM | lld:pubmed |
| pubmed-article:9546433 | pubmed:author | pubmed-author:SpooncerEE | lld:pubmed |
| pubmed-article:9546433 | pubmed:author | pubmed-author:HeyworthC MCM | lld:pubmed |
| pubmed-article:9546433 | pubmed:author | pubmed-author:WhettonA DAD | lld:pubmed |
| pubmed-article:9546433 | pubmed:author | pubmed-author:WarmAA | lld:pubmed |
| pubmed-article:9546433 | pubmed:author | pubmed-author:FrancisJ MJM | lld:pubmed |
| pubmed-article:9546433 | pubmed:author | pubmed-author:CzaplewskiLL | lld:pubmed |
| pubmed-article:9546433 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9546433 | pubmed:day | 12 | lld:pubmed |
| pubmed-article:9546433 | pubmed:volume | 16 | lld:pubmed |
| pubmed-article:9546433 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9546433 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9546433 | pubmed:pagination | 1319-24 | lld:pubmed |
| pubmed-article:9546433 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:9546433 | pubmed:meshHeading | pubmed-meshheading:9546433-... | lld:pubmed |
| pubmed-article:9546433 | pubmed:meshHeading | pubmed-meshheading:9546433-... | lld:pubmed |
| pubmed-article:9546433 | pubmed:meshHeading | pubmed-meshheading:9546433-... | lld:pubmed |
| pubmed-article:9546433 | pubmed:meshHeading | pubmed-meshheading:9546433-... | lld:pubmed |
| pubmed-article:9546433 | pubmed:meshHeading | pubmed-meshheading:9546433-... | lld:pubmed |
| pubmed-article:9546433 | pubmed:meshHeading | pubmed-meshheading:9546433-... | lld:pubmed |
| pubmed-article:9546433 | pubmed:meshHeading | pubmed-meshheading:9546433-... | lld:pubmed |
| pubmed-article:9546433 | pubmed:meshHeading | pubmed-meshheading:9546433-... | lld:pubmed |
| pubmed-article:9546433 | pubmed:meshHeading | pubmed-meshheading:9546433-... | lld:pubmed |
| pubmed-article:9546433 | pubmed:meshHeading | pubmed-meshheading:9546433-... | lld:pubmed |
| pubmed-article:9546433 | pubmed:meshHeading | pubmed-meshheading:9546433-... | lld:pubmed |
| pubmed-article:9546433 | pubmed:meshHeading | pubmed-meshheading:9546433-... | lld:pubmed |
| pubmed-article:9546433 | pubmed:meshHeading | pubmed-meshheading:9546433-... | lld:pubmed |
| pubmed-article:9546433 | pubmed:meshHeading | pubmed-meshheading:9546433-... | lld:pubmed |
| pubmed-article:9546433 | pubmed:meshHeading | pubmed-meshheading:9546433-... | lld:pubmed |
| pubmed-article:9546433 | pubmed:meshHeading | pubmed-meshheading:9546433-... | lld:pubmed |
| pubmed-article:9546433 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9546433 | pubmed:articleTitle | Abl protein kinase abrogates the response of multipotent haemopoietic cells to the growth inhibitor macrophage inflammatory protein-1 alpha. | lld:pubmed |
| pubmed-article:9546433 | pubmed:affiliation | Leukaemia Research Fund Cellular Development Unit, UMIST, Manchester, UK. | lld:pubmed |
| pubmed-article:9546433 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9546433 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9546433 | lld:pubmed |
